SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-22-027687
Filing Date
2022-02-04
Accepted
2022-02-04 07:07:55
Documents
14
Period of Report
2022-02-04
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d302458d8k.htm   iXBRL 8-K 25440
2 EX-99.1 d302458dex991.htm EX-99.1 14433
6 GRAPHIC g302458g0204091239164.jpg GRAPHIC 4026
  Complete submission text file 0001193125-22-027687.txt   173335

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA vnda-20220204.xsd EX-101.SCH 2895
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE vnda-20220204_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE vnda-20220204_pre.xml EX-101.PRE 11287
8 EXTRACTED XBRL INSTANCE DOCUMENT d302458d8k_htm.xml XML 3366
Mailing Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037
Business Address 2200 PENNSYLVANIA AVE NW SUITE 300E WASHINGTON DC 20037 202-734-3400
Vanda Pharmaceuticals Inc. (Filer) CIK: 0001347178 (see all company filings)

IRS No.: 030491827 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34186 | Film No.: 22590959
SIC: 2834 Pharmaceutical Preparations